Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.75 |
| ▸ | HTR4 | Q13639 | 11/20 | 0.70 |
| ▸ | HTR3A | P46098 | 1/20 | 0.70 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6246866 | 0.90 | KCNH2 (0.61) | KCNH2HTR4HTR3ACACNA1IDRD2 | |
| SCHEMBL5889579 | 0.89 | KCNH2 (0.77) | KCNH2HTR4HTR3ACACNA1IDRD2 | |
| SCHEMBL6246478 | 0.89 | KCNH2 (0.76) | KCNH2HTR4HTR3ACACNA1IDRD2 | |
| SCHEMBL6314948 | 0.86 | KCNH2 (0.81) | KCNH2HTR4HTR3ACACNA1I | |
| SCHEMBL6703834 | 0.86 | KCNH2 (0.73) | KCNH2HTR4HTR3ADRD2DRD4 | |
| SCHEMBL5889452 | 0.86 | KCNH2 (0.73) | KCNH2HTR4HTR3ADRD2DRD4 | |
| SCHEMBL5889425 | 0.86 | KCNH2 (1.00) | KCNH2HTR4HTR3ACACNA1I | |
| SCHEMBL6703982 | 0.85 | KCNH2 (0.74) | KCNH2HTR4HTR3A | |
| SCHEMBL6178204 | 0.85 | KCNH2 (0.76) | KCNH2HTR4HTR3A | |
| SCHEMBL6703420 | 0.85 | HTR4 (0.71) | KCNH2HTR4HTR3ADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951867-B2 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-10-04 | — | — | US | claimed |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2004-07-01 | — | — | US | claimed |
| US-6951867-B2 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543004-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER INC. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| WO-2004026868-A1 | N-SUBSTITUTED PIPERIDINYL-IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | KCNH2 1390/4885HTR4 1/4885HTR3A 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.